150 related articles for article (PubMed ID: 18797423)
1. Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study.
Kurosaki I; Kawachi Y; Nihei K; Tsuchiya Y; Aono T; Yokoyama N; Shimizu T; Hatakeyama K
Pancreas; 2009 Mar; 38(2):161-7. PubMed ID: 18797423
[TBL] [Abstract][Full Text] [Related]
2. A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer.
Okusaka T; Ishii H; Funakoshi A; Ueno H; Furuse J; Sumii T
Jpn J Clin Oncol; 2006 Sep; 36(9):557-63. PubMed ID: 16870696
[TBL] [Abstract][Full Text] [Related]
3. 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome.
Spry N; Harvey J; Macleod C; Borg M; Ngan SY; Millar JL; Graham P; Zissiadis Y; Kneebone A; Carroll S; Davies T; Reece WH; Iacopetta B; Goldstein D
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1438-46. PubMed ID: 18164859
[TBL] [Abstract][Full Text] [Related]
4. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K
Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer.
Nakayama S; Takeda S; Kawase Y; Inoue S; Kaneko T; Nakao A
Ann Surg; 2004 Nov; 240(5):840-4. PubMed ID: 15492566
[TBL] [Abstract][Full Text] [Related]
6. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Regine WF; Winter KA; Abrams R; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Rich TA; Willett CG
Ann Surg Oncol; 2011 May; 18(5):1319-26. PubMed ID: 21499862
[TBL] [Abstract][Full Text] [Related]
7. Continuous transarterial infusion chemotherapy with gemcitabine and 5-Fluorouracil for advanced pancreatic carcinoma.
Hong GB; Zhou JX; Sun HB; Li CY; Song LQ
Asian Pac J Cancer Prev; 2012; 13(6):2669-73. PubMed ID: 22938439
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Neoptolemos JP; Stocken DD; Bassi C; Ghaneh P; Cunningham D; Goldstein D; Padbury R; Moore MJ; Gallinger S; Mariette C; Wente MN; Izbicki JR; Friess H; Lerch MM; Dervenis C; Oláh A; Butturini G; Doi R; Lind PA; Smith D; Valle JW; Palmer DH; Buckels JA; Thompson J; McKay CJ; Rawcliffe CL; Büchler MW;
JAMA; 2010 Sep; 304(10):1073-81. PubMed ID: 20823433
[TBL] [Abstract][Full Text] [Related]
9. 5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer.
Takamori H; Kanemitsu K; Tsuji T; Tanaka H; Chikamoto A; Nakahara O; Hiraoka T; Ikeda O; Kudo K; Imuta M; Yamashita Y
Pancreas; 2005 Apr; 30(3):223-6. PubMed ID: 15782098
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.
Lim KH; Kim TY; Lee KH; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1017-26. PubMed ID: 21327930
[TBL] [Abstract][Full Text] [Related]
11. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
[TBL] [Abstract][Full Text] [Related]
12. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Scheithauer W; Schüll B; Ulrich-Pur H; Schmid K; Raderer M; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Kornek GV
Ann Oncol; 2003 Jan; 14(1):97-104. PubMed ID: 12488300
[TBL] [Abstract][Full Text] [Related]
13. Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.
Wilkowski R; Thoma M; Bruns C; Wagner A; Heinemann V
JOP; 2006 Jul; 7(4):349-60. PubMed ID: 16832132
[TBL] [Abstract][Full Text] [Related]
14. Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer.
Takamori H; Kanemitsu K; Hirota M; Ikeda O; Tanaka H; Beppu T; Yamashita Y; Oya N; Baba H
Ann Surg Oncol; 2011 Apr; 18(4):1110-5. PubMed ID: 21046268
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
[TBL] [Abstract][Full Text] [Related]
16. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
[TBL] [Abstract][Full Text] [Related]
17. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Reni M; Cereda S; Mazza E; Passoni P; Nicoletti R; Balzano G; Zerbi A; Arcidiacono PG; Staudacher C; Di Carlo V
Am J Clin Oncol; 2008 Apr; 31(2):145-50. PubMed ID: 18391598
[TBL] [Abstract][Full Text] [Related]
18. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
[TBL] [Abstract][Full Text] [Related]
19. Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).
Roehrig S; Wein A; Albrecht H; Konturek PC; Reulbach U; Männlein G; Wolff K; Ostermeier N; Hohenberger W; Hahn EG; Boxberger F
Med Sci Monit; 2010 Mar; 16(3):CR124-131. PubMed ID: 20190682
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of intra-arterial pharmacokinetic chemotherapy with 5-fluorouracil, CDDP, gemcitabine, and angiotensin-II in patients with advanced pancreatic cancer.
Ishikawa T; Kamimura H; Tsuchiya A; Togashi T; Watanabe K; Seki K; Ohta H; Yoshida T; Takeda K; Kamimura T
Hepatogastroenterology; 2007 Dec; 54(80):2378-82. PubMed ID: 18265669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]